Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Clinical trial NCT04709458 · UNKNOWN

Trial details

NCT number: NCT04709458
Sponsor: Taiga Biotechnologies, Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Myelofibrosis Acute Myelogenous Leukemia

Start date: 2022-09-01
Primary completion: 2024-08-28
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.